Establishment of a Shigella Sonnei Human Challenge Model in Thailand

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2012 Oct 17

PMID 23069701

Citations 18

Authors

Ladaporn Bodhidatta

Punnee Pitisuttithum

Supat Chamnanchanant

Karen T Chang

Dilara Islam

Valai Bussaratid

Malabi M Venkatesan

Thomas L Hale

Carl J Mason

Affiliations

Soon will be listed here.

Abstract

In order to establish a human challenge model of Shigella related disease for vaccine testing, a dose-escalating inpatient trial was performed. Three groups of 12 healthy adult volunteers were orally challenged with 93,440 and 1680 CFU of Shigella sonnei strain 53G. Subjects were admitted to the Vaccine Trial Centre (VTC) at Mahidol University in Bangkok, Thailand. The primary purpose of this study was to identify the dose of S. sonnei 53G required to elicit clinical disease in at least 70% of Thai adult subjects. At the highest dose of 1680 CFU, the attack rate was 75%, while at the two lower doses, the attack rate was approximately 50%. This human challenge model, which is the first of its kind in an endemic region, will provide an opportunity for S. sonnei vaccine evaluation in endemic populations.

Citing Articles

Controlled human malaria infection: overview and potential application in the evaluation of transmission-blocking interventions in malaria-endemic areas.

Kessy E, Olotu A Malar J. 2025; 24(1):33.

PMID: 39893367 PMC: 11786456. DOI: 10.1186/s12936-025-05277-x.

Experiences, perceptions and ethical considerations of the malaria infection study in Thailand.

Naemiratch B, Kulpijit N, Ruangkajorn S, Day N, Prachumsri J, Cheah P BMC Med Ethics. 2025; 26(1):14.

PMID: 39875955 PMC: 11773921. DOI: 10.1186/s12910-024-01160-7.

Protocol for the challenge non-typhoidal (CHANTS) study: a first-in-human, in-patient, double-blind, randomised, safety and dose-escalation controlled human infection model in the UK.

Smith C, Smith E, Rydlova A, Varro R, Hinton J, Gordon M BMJ Open. 2024; 14(1):e076477.

PMID: 38199617 PMC: 10806722. DOI: 10.1136/bmjopen-2023-076477.

Controlled Human Infection Models To Accelerate Vaccine Development.

Choy R, Louis Bourgeois A, Ockenhouse C, Walker R, Sheets R, Flores J Clin Microbiol Rev. 2022; 35(3):e0000821.

PMID: 35862754 PMC: 9491212. DOI: 10.1128/cmr.00008-21.

Shigella-Controlled Human Infection Models: Current and Future Perspectives.

Clarkson K, Porter C, Talaat K, Kapulu M, Chen W, Frenck Jr R Curr Top Microbiol Immunol. 2022; 445:257-313.

PMID: 35616717 PMC: 7616482. DOI: 10.1007/82_2021_248.

References

Cohen D, Green M, Block C, Slepon R, Ofek I . Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol. 1991; 29(2):386-9. PMC: 269772. DOI: 10.1128/jcm.29.2.386-389.1991. View

DuPont H, Hornick R, Dawkins A, Snyder M, Formal S . The response of man to virulent Shigella flexneri 2a. J Infect Dis. 1969; 119(3):296-9. DOI: 10.1093/infdis/119.3.296. View

Spiller R . Role of infection in irritable bowel syndrome. J Gastroenterol. 2007; 42 Suppl 17:41-7. DOI: 10.1007/s00535-006-1925-8. View

Orr N, ROBIN G, Lowell G, Cohen D . Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with Shigella sonnei. J Clin Microbiol. 1992; 30(8):2165-8. PMC: 265463. DOI: 10.1128/jcm.30.8.2165-2168.1992. View

Kweon M . Shigellosis: the current status of vaccine development. Curr Opin Infect Dis. 2008; 21(3):313-8. DOI: 10.1097/QCO.0b013e3282f88b92. View

Hartman A, Venkatesan M . Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infect Immun. 1998; 66(9):4572-6. PMC: 108562. DOI: 10.1128/IAI.66.9.4572-4576.1998. View

Cohen D, Orr N, ROBIN G, Slepon R, Ashkenazi S, Ashkenazi I . Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination. Clin Diagn Lab Immunol. 1996; 3(4):451-5. PMC: 170366. DOI: 10.1128/cdli.3.4.451-455.1996. View

Black R, Levine M, Clements M, Losonsky G, Herrington D, Berman S . Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis. 1987; 155(6):1260-5. DOI: 10.1093/infdis/155.6.1260. View

Van de Verg L, Herrington D, Murphy J, Wasserman S, Formal S, Levine M . Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun. 1990; 58(6):2002-4. PMC: 258758. DOI: 10.1128/iai.58.6.2002-2004.1990. View

10.

Munoz C, Baqar S, Van de Verg L, Thupari J, Goldblum S, Olson J . Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances. Am J Trop Med Hyg. 1995; 53(1):47-54. View

11.

Kotloff K, Nataro J, Losonsky G, Wasserman S, Hale T, Taylor D . A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine. 1995; 13(16):1488-94. DOI: 10.1016/0264-410x(95)00102-7. View

12.

Kotloff K, Losonsky G, Nataro J, Wasserman S, Hale T, Taylor D . Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine. 1995; 13(5):495-502. DOI: 10.1016/0264-410x(94)00011-b. View

13.

Chompook P, Samosornsuk S, von Seidlein L, Jitsanguansuk S, Sirima N, Sudjai S . Estimating the burden of shigellosis in Thailand: 36-month population-based surveillance study. Bull World Health Organ. 2005; 83(10):739-46. PMC: 2626425. DOI: /S0042-96862005001000010. View

14.

Kosek M, Penataro Yori P, Paredes Olortegui M . Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas. Curr Opin Infect Dis. 2010; 23(5):475-80. PMC: 6892429. DOI: 10.1097/QCO.0b013e32833da204. View

15.

Gaston J, Lillicrap M . Arthritis associated with enteric infection. Best Pract Res Clin Rheumatol. 2003; 17(2):219-39. DOI: 10.1016/s1521-6942(02)00104-3. View

16.

Orr N, Katz D, Atsmon J, Radu P, Yavzori M, Halperin T . Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun. 2005; 73(12):8027-32. PMC: 1307051. DOI: 10.1128/IAI.73.12.8027-8032.2005. View

17.

Herrington D, Van de Verg L, Formal S, Hale T, Tall B, Cryz S . Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine. 1990; 8(4):353-7. DOI: 10.1016/0264-410x(90)90094-3. View

18.

Isenbarger D, Hoge C, Srijan A, Pitarangsi C, Vithayasai N, Bodhidatta L . Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999. Emerg Infect Dis. 2002; 8(2):175-80. PMC: 3369583. DOI: 10.3201/eid0802.010145. View

19.

Kuo C, Su L, Perera J, Carlos C, Tan B, Kumarasinghe G . Antimicrobial susceptibility of Shigella isolates in eight Asian countries, 2001-2004. J Microbiol Immunol Infect. 2008; 41(2):107-11. View

20.

Barnoy S, Baqar S, Kaminski R, Collins T, Nemelka K, Hale T . Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. Vaccine. 2011; 29(37):6371-8. DOI: 10.1016/j.vaccine.2011.04.115. View